CATX · Why this verdict
Why Perspective Therapeutics (CATX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.1/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company posts extreme cash burn (free cash flow at roughly -9,512% of revenue) and a weak Piotroski F-Score of 2 out of 9, keeping the quality score at 1.2 versus the engine's 4.0 floor. Quality breakdown | Piotroski F-Score should climb toward 5 or higher and free cash flow should move toward breakeven over the next 12 months. | →Stable |
| CounterClinical-stage medical device companies routinely burn cash while funding trials and commercial launch, so a single period's FCF ratio may overstate the underlying quality problem. | ||
Momentum is stretched, with RSI at 78 and moving-average slope flat to negative even as on-balance volume shows accumulation, a combination the engine flags as late-cycle distribution risk. Momentum breakdown | RSI should cool into a 40-60 range without a sharp price breakdown if the current advance is durable. | →Stable |
| CounterOverbought readings can persist through extended uptrends in momentum-driven small caps, so RSI alone is a weak timing signal. | ||
The company has missed earnings estimates in 3 of the last 4 quarters, with an average surprise of -9.4%, undercutting confidence in near-term execution. Earnings | The beat rate should improve to majority-beat (3 of 4 or better) with average surprise turning positive over the next four reported quarters. | →Stable |
| CounterA single recent quarter beat (the most recent print, +21.7% surprise) could mark an inflection after a rough stretch, especially for an early-stage company where estimates are volatile. | ||
The stock's targets show minimal upside room to its $3.70 take-profit level (1.9% upside) against a $3.38 stop-loss (6.9% downside), a tight, asymmetric risk-reward setup. Targets | Upside to take-profit should widen to at least 10% without the stop-loss level moving further away, if the setup improves. | →Stable |
| CounterTight technical targets can reflect a stock consolidating near resistance ahead of a breakout, not necessarily a poor risk/reward. | ||
The company posts extreme cash burn (free cash flow at roughly -9,512% of revenue) and a weak Piotroski F-Score of 2 out of 9, keeping the quality score at 1.2 versus the engine's 4.0 floor.
→StableQuality breakdown
- Expectation
- Piotroski F-Score should climb toward 5 or higher and free cash flow should move toward breakeven over the next 12 months.
CounterClinical-stage medical device companies routinely burn cash while funding trials and commercial launch, so a single period's FCF ratio may overstate the underlying quality problem.
Momentum is stretched, with RSI at 78 and moving-average slope flat to negative even as on-balance volume shows accumulation, a combination the engine flags as late-cycle distribution risk.
→StableMomentum breakdown
- Expectation
- RSI should cool into a 40-60 range without a sharp price breakdown if the current advance is durable.
CounterOverbought readings can persist through extended uptrends in momentum-driven small caps, so RSI alone is a weak timing signal.
The company has missed earnings estimates in 3 of the last 4 quarters, with an average surprise of -9.4%, undercutting confidence in near-term execution.
→StableEarnings
- Expectation
- The beat rate should improve to majority-beat (3 of 4 or better) with average surprise turning positive over the next four reported quarters.
CounterA single recent quarter beat (the most recent print, +21.7% surprise) could mark an inflection after a rough stretch, especially for an early-stage company where estimates are volatile.
The stock's targets show minimal upside room to its $3.70 take-profit level (1.9% upside) against a $3.38 stop-loss (6.9% downside), a tight, asymmetric risk-reward setup.
→StableTargets
- Expectation
- Upside to take-profit should widen to at least 10% without the stop-loss level moving further away, if the setup improves.
CounterTight technical targets can reflect a stock consolidating near resistance ahead of a breakout, not necessarily a poor risk/reward.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Perspective Therapeutics screens as a high-risk small-cap medical device name: severe cash burn and weak fundamental quality metrics, an overbought momentum setup flagged for late-cycle distribution risk, a recent stretch of earnings misses, and a tight, asymmetric risk-reward profile all argue for caution over the next 12 months.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 2.5 |
| Piotroski F | 2.2 |
- ▸Cash-burning: FCF -9512% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.3 |
| MACD | 7.8 |
| OBV | 10.0 |
| MA position | 4.5 |
| Volume | 0.5 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 279%
Insider
5.2/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.3 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 1.1 |
| growth rank | 0.0 |
Technical
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.3 |
| support resistance | 3.9 |
| 52w position | 1.1 |
| gap | 5.0 |
Risk (lower is worse)
1.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.9 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 0.0 |
| beta | 4.2 |
| debt equity | 4.6 |
- ▸Elevated put/call: 10.00
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:5.2>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:38d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (3)
- MOMENTUM:5.2<5.5 (soft — BUY_NOW allowed but watch)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- DEATH_CROSS:momentum=5.2>=5.0 recovering
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 67
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -45% (>40% off 52w high)
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 6.6 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 6.6, Momentum at 5.2, and Insider at 5.2; the weakest are Quality at 1.2, Risk (lower is worse) at 1.9, and Catalyst at 2.5. The V9 engine cleared all gates with 3 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Severe Cash Burn Quality Gap
Trip ifPiotroski F-Score rises to 5 or higher out of 9.
- P2Overbought Momentum Distribution Risk
Trip ifRSI stays above 70 for 3 more consecutive months while price rises more than 20%.
- P3Earnings Miss Trend Risk
Trip ifAverage earnings surprise rises above 0% across the next 2 reported quarters.
- P4Asymmetric Risk Reward Skew
Trip ifUpside to take-profit rises above 10% while downside to stop-loss stays below 7%.